Skip to main content
Premium Trial:

Request an Annual Quote

Proteome Sciences Wins Over $1M From EU, UK Government

NEW YORK, Feb. 13 (GenomeWeb News) - Proteome Sciences has won

438,000 ($563,000) from the European Union, and £419,000 ($794,000) from the UK government, to conduct research into anti-depressant drugs and into Alzheimer's disease, respectively, the company said today.


The EU award is part of a 7.5 million, three-year multi-center pharmacogenomics grant from the EU's 6th Framework Program. Proteome Sciences will explore patients' response to anti-depressants, with the aim to predict responders, find early disease indicators, and discover new drug targets.


The UK government grant, jointly awarded to Cobham, UK-based Proteome Sciences and the Institute of Psychiatry at Kings College, London, will fund the discovery of new biomarkers and targets for Alzheimer's.


The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.